Management of Hereditary Angioedema Type 1 and 2 for Canadian Allergy and Immunology Practitioners
DOI:
https://doi.org/10.58931/cait.2023.3142Abstract
It is imperative for allergists and immunologists to accurately confirm the diagnosis of HAE and coordinate individualized, patient-centred treatment. The 2019 International/Canadian Hereditary Angioedema Guideline, provides an evidence-based approach to managing HAE patients. The objective of this article is to further assist healthcare providers in caring for patients with a confirmed diagnosis of HAE by outlining an approach to patient counselling and reviewing the principles of therapy. We propose 5 essential items to consider in the management of all HAE patients: 1) Patient education; 2) On-demand therapy; 3) Short-term prophylaxis (STP); 4) Long-term prophylaxis (LTP); and 5) Genetic testing. We will also discuss special considerations for pregnant patients.
References
Kanani A, et al. Urticaria and Angioedema. Allergy Asthma Clin Immunol. 2018 Sep;14(2):59. doi:10.1186/s13223-018-0288-z
Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996 Jun 20;334(25):1666-7. doi:10.1056/NEJM199606203342508
Zuraw BL. Hereditary angioedema. N Engl J Med. 2008 Sep 4;359(10):1027-36. doi:10.1056/NEJMra0801636
Betschel S, et al. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol. 2019 Nov;15(1):72. doi:10.1186/s13223-019-0376-8
CSL Behring Canada Inc. Berinert Product Monograph. Mississauga, ON: CSL Behring Canada Inc., 2022.
Takeda Canada Inc. Firazyr Product Monograph. Oakville, ON: Takeda Canada Inc., 2022.
Betschel S, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014 Oct;10(1):50. doi:10.1186/1710-1492-10-50
Shire Pharma Canada ULC. Cinryze Product Monograph. Toronto, ON: Shire Pharma Canada ULC, 2022.
Pharming Healthcare Inc. Kalbitor Product Monograph. Mississauga, ON: Pharming Healthcare Inc., 2021.
Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract. 2005 May;59(5):594-599. doi:10.1111/j.1368-5031.2005.00553.x
Zuraw BL, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):513-22. doi:10.1056/NEJMoa0805538
CSL Behring Canada Inc. Haegarda Product Monograph. Mississauga, ON: CSL Behring Canada Inc., 2022.
CADTH. Canadian drug expert committee recommendation: lanadelumab (Takhzyro-Shire Pharma Canada ULC): indication: for the routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults. Canadian Agency for Drugs and Technologies in Health, 2019.
Takeda Canada Inc. TAKHZYRO Product Monograph. Oakville, ON: Takeda Canada Inc., 2022.
BioCryst Pharmaceuticals, Inc. Orladeyo Product Monograph. Mississauga, ON: BioCryst Pharmaceuticals, Inc.; 2021.
Roach B, Stiehm ER, Borte M, et al. Influence of age and sex on serum complement components in children. Am J Dis Child. 1981 Oct;135(10):918-920.
![Management of Hereditary Angioedema Type 1 and 2 for Canadian Allergy and Immunology Practitioners](https://canadianallergyandimmunologytoday.com/public/journals/1/submission_42_42_coverImage_en_US.png)